<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clinics (Sao Paulo)</journal-id><journal-title-group><journal-title>Clinics</journal-title></journal-title-group><issn pub-type="ppub">1807-5932</issn><issn pub-type="epub">1980-5322</issn><publisher><publisher-name>Hospital das Cl&#x000ed;nicas da Faculdade de Medicina da Universidade de S&#x000e3;o Paulo</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20037706</article-id><article-id pub-id-type="pmc">2797587</article-id><article-id pub-id-type="doi">10.1590/S1807-59322009001200008</article-id><article-id pub-id-type="publisher-id">cln_64p1187</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Science</subject></subj-group></article-categories><title-group><article-title>Effectiveness of Radiation Synovectomy with Samarium-153 Particulate Hydroxyapatite in Rheumatoid Arthritis Patients with Knee Synovitis: A Controlled Randomized Double-Blind Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>dos Santos</surname><given-names>Marla Francisca</given-names></name><xref ref-type="aff" rid="af1-cln64_12p1187">I</xref></contrib><contrib contrib-type="author"><name><surname>Furtado</surname><given-names>Rita Nely Vilar</given-names></name><xref ref-type="aff" rid="af1-cln64_12p1187">I</xref></contrib><contrib contrib-type="author"><name><surname>Konai</surname><given-names>Monique Sayuri</given-names></name><xref ref-type="aff" rid="af1-cln64_12p1187">I</xref></contrib><contrib contrib-type="author"><name><surname>Castiglioni</surname><given-names>Mario Luiz Vieira</given-names></name><xref ref-type="aff" rid="af2-cln64_12p1187">II</xref></contrib><contrib contrib-type="author"><name><surname>Marchetti</surname><given-names>Renata Rosa</given-names></name><xref ref-type="aff" rid="af2-cln64_12p1187">II</xref></contrib><contrib contrib-type="author"><name><surname>Natour</surname><given-names>Jamil</given-names></name><xref ref-type="aff" rid="af1-cln64_12p1187">I</xref><xref ref-type="corresp" rid="c1-cln64_12p1187"/></contrib></contrib-group><aff id="af1-cln64_12p1187"><label>I</label> Division of Rheumatology, Universidade Federal de S&#x000e3;o Paulo, Escola Paulista de Medicina (UNIFESP) - S&#x000e3;o Paulo/SP, Brazil</aff><aff id="af2-cln64_12p1187"><label>II</label> Department of Radiology, Division of Nuclear Medicine, Universidade Federal de S&#x000e3;o Paulo, Escola Paulista de Medicina (UNIFESP) - S&#x000e3;o Paulo/SP, Brazil.</aff><author-notes><corresp id="c1-cln64_12p1187">Email: 
<email>jnatour@unifesp.br</email> Tel. : 55 11 5576.4239</corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2009</year></pub-date><volume>64</volume><issue>12</issue><fpage>1187</fpage><lpage>1193</lpage><history><date date-type="received"><day>28</day><month>6</month><year>2009</year></date><date date-type="accepted"><day>17</day><month>9</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Hospital das Cl&#x000ed;nicas da FMUSP</copyright-statement></permissions><abstract><sec><title>OBJECTIVES:</title><p>The aim of the present study was to investigate the effectiveness of Samarium<sup>153</sup>-particulate hydroxyapatite radiation synovectomy in rheumatoid arthritis patients with chronic knee synovitis.</p></sec><sec><title>METHODS:</title><p>Fifty-eight rheumatoid arthritis patients (60 knees) with chronic knee synovitis participated in a controlled double-blinded trial. Patients were randomized to receive either an intra-articular injection with 40 mg triamcinolone hexacetonide alone (TH group) or 40 mg triamcinolone hexacetonide combined with 15 mCi Samarium<sup>153</sup>-particulate hydroxyapatite (Sm/TH group). Blinded examination at baseline (T0) and at 1 (T1), 4 (T4), 12 (T12), 32 (T32), and 48 (T48) weeks post-intervention were performed on all patients and included a visual analog scale for joint pain and swelling as well as data on morning stiffness, flexion, extension, knee circumference, Likert scale of improvement, percentage of improvement, SF-36 generic quality of life questionnaire, Stanford Health Assessment Questionnaire (HAQ), Lequesne index, use of non-steroidal anti-inflammatory drugs or oral corticosteroids, events and adverse effects, calls to the physician, and hospital visits.</p></sec><sec><title>RESULTS:</title><p>The sample was homogeneous at baseline, and there were no withdrawals. Improvement was observed in both groups in relation to T0, but no statistically significant differences between groups were observed regarding all variables at the time points studied. The Sm/TH group exhibited more adverse effects at T1 (p&#x0003c;0.05), but these were mild and transitory. No severe adverse effects were reported during follow-up.</p></sec><sec><title>CONCLUSION:</title><p>Intra-articular injection of Samarium<sup>153</sup>-particulate hydroxyapatite (15 mCi) with 40 mg of triamcinolone hexacetonide is not superior to triamcinolone hexacetonide alone for the treatment of knee synovitis in patients with rheumatoid arthritis at 1 y of follow-up.</p></sec></abstract><kwd-group><kwd>Rheumatoid arthritis</kwd><kwd>Intra-articular injection</kwd><kwd>Radiosynoviorthesis</kwd><kwd>Radiation synovectomy</kwd><kwd>Samarium</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Rheumatoid arthritis (RA) is a chronic disease that is mainly characterized by asymmetric erosive synovitis, particularly affecting peripheral joints.<xref ref-type="bibr" rid="b1-cln64_12p1187">1</xref> Functional disability in patients with RA is the consequence of joint deformity, which is the result of pannus invasion of the articular cartilage, capsule, ligaments and subchondral bone.<xref ref-type="bibr" rid="b2-cln64_12p1187">2</xref> Current treatment for RA is based on a pharmacological approach,<xref ref-type="bibr" rid="b3-cln64_12p1187">3</xref> physical therapy,<xref ref-type="bibr" rid="b4-cln64_12p1187">4</xref> and patient education.<xref ref-type="bibr" rid="b5-cln64_12p1187">5</xref> Synovectomy through chemical, radioisotopic, or surgical means has been adopted as a therapeutic option in RA.<xref ref-type="bibr" rid="b6-cln64_12p1187">6</xref>,<xref ref-type="bibr" rid="b7-cln64_12p1187">7</xref> Most chemical synovectomy is performed using intra-articular injection (IAI) of glucocorticosteroids, the most effective of which has been shown to be triamcinolone hexacetonide (TH).<xref ref-type="bibr" rid="b8-cln64_12p1187">8</xref></p><p>Radiation synovectomy (RS) (also called radio-synoviorthesis or radiosynovectomy) is a local IAI of radionuclides in colloidal form for radiotherapy. First used by Fellinger et al.<xref ref-type="bibr" rid="b9-cln64_12p1187">9</xref> in 1952, the technique has been applied for over 50 y in the treatment of resistant synovitis in individual joints after the failure of long-term systemic pharmacotherapy and intra-articular steroid injections. Radioisotopes with emission of &#x003b2; radiation have the capacity to diminish the inflammatory process and ablate the inflamed synovial membrane (pannus) with subsequent fibrosis.<xref ref-type="bibr" rid="b10-cln64_12p1187">10</xref> Three radionuclides are currently in use: Yttrium-90 (<sup>90</sup>Y-silicate/citrate), Rhenium-186 (<sup>186</sup>Re-sulfide), and Erbium-169 (<sup>169</sup>Er citrate), which have been indicated for large, medium, and small joints, respectively.<xref ref-type="bibr" rid="b10-cln64_12p1187">10</xref> These radionuclides are indicated for treatment of joint pain arising from arthropathies, including RA, spondyloarthropathy, other inflammatory joint diseases (Lyme disease, Beh&#x000e7;et&#x02019;s disease), persistent synovial effusion, hemophilic arthritis, calcium pyrophosphate dihydrate arthritis, pigmented villonodular synovitis, and undifferentiated arthritis.<xref ref-type="bibr" rid="b10-cln64_12p1187">10</xref>,<xref ref-type="bibr" rid="b12-cln64_12p1187">12</xref></p><p>In clinical practice, RS is a procedure that has been widely used for several decades, mainly in European countries, Australia, and Canada,<xref ref-type="bibr" rid="b11-cln64_12p1187">11</xref> especially for patients with refractory synovitis, (synovitis that fails to respond to at least one intra-articular injection with corticosteroids).<xref ref-type="bibr" rid="b12-cln64_12p1187">12</xref></p><p>Despite the established use of RS in clinical practice, there are few randomized, controlled studies using this technique in relation to the most often used radioisotopes: <sup>186</sup>Re, <sup>169</sup>Er and <sup>90</sup>Y.<xref ref-type="bibr" rid="b7-cln64_12p1187">7</xref>,<xref ref-type="bibr" rid="b10-cln64_12p1187">10</xref>,<xref ref-type="bibr" rid="b12-cln64_12p1187">12</xref>&#x02013;<xref ref-type="bibr" rid="b24-cln64_12p1187">24</xref> Samarium<sup>153</sup>-hydroxyapatite (<sup>153</sup>SmPHYP) is considered another option for RS<xref ref-type="bibr" rid="b25-cln64_12p1187">25</xref>,<xref ref-type="bibr" rid="b26-cln64_12p1187">26</xref>; however, there are few well-conducted studies in the literature using <sup>153</sup>SmPHYP for the treatment of chronic synovitis. Therefore, we decided to develop a randomized controlled double-blinded study that aimed to investigate the effectiveness of <sup>153</sup>SmPHYP in RS for chronic knee synovitis in patients with RA.</p></sec><sec sec-type="methods|subjects"><title>PATIENTS AND METHODS</title><p>A controlled, randomized, double-blind prospective study was carried out comparing RS to <sup>153</sup>SmPHYP associated with TH versus IAI with TH alone for the treatment of knee synovitis in patients with RA.</p><sec sec-type="subjects"><title>Patients</title><p>This study included 58 consecutive patients (60 joints) with RA and chronic knee synovitis. Patients were recruited from the Rheumatology Outpatient Clinics at the Universidade Federal de S&#x000e3;o Paulo (UNIFESP), S&#x000e3;o Paulo, Brazil. The following were the inclusion criteria: diagnosis of RA (according to the ACR criteria) at least 6 mo prior to recruitment;<xref ref-type="bibr" rid="b27-cln64_12p1187">27</xref> chronic monoarticular knee synovitis or oligoarticular arthritis with the knee being the more symptomatic joint for over 6 wks; age between 18 and 60 y; use of stable doses of oral corticosteroids for the previous 30 d and use of stable doses of DMARDs (disease modifying antirheumatic drugs) for the previous 3 mo; a score between 5 and 10 on a visual analog scale for pain (VAS, range 0&#x02013;10 cm); reading and writing skills; and no risk of pregnancy (women with a history of hysterectomy, tubal ligation, or menopause). Written informed consent was obtained from all subjects, and the Ethics Committee approved the study. Exclusion criteria were as follows: patients with collagen diseases other than RA; pregnant or breast-feeding women; intra-articular knee injection in the previous 3 mo (or other joints); prior knee surgery or skin lesion; suspected septic arthritis or ruptured popliteal cyst (knee); urinary incontinence; any intervention in the knee in the previous 3 mo. Radiographs were performed with loads on the knees submitted to the procedure at the beginning of the study and later classified through &#x0201c;blinded&#x0201d; radiographic analysis according to the Kellgren-Lawrence scale for secondary osteoarthritis.<xref ref-type="bibr" rid="b28-cln64_12p1187">28</xref></p><p>After a period of 3 mo of follow-up, the patients could have their DMARDs modified. We opted for that flexibility in order to provide better clinical control of the disease and to increase the adherence of the patients.</p></sec><sec><title>Intervention</title><p>Lots with opaque sealed envelopes were used to randomly and equally allocate patients into two intervention groups: TH group, in which 30 patients (30 knees) received an IAI in the knee with 40 mg triamcinolone hexacetonide (TH) alone; and Sm/TH group, in which 28 patients (30 knees) received 40 mg TH combined with 15 mCi <sup>153</sup>SmPHYP. Both procedures were performed by the same researcher, and assessments were carried out by a blinded evaluator. In the case of bilateral synovitis, the knee with the higher visual analogue score (VAS) for pain was infiltrated. Inclusion of the same patient in the study for a second time was permitted if he/she fulfilled the inclusion criteria after three months from the initial intervention and exhibited arthritis in the contralateral knee. Inclusion a second time for the same knee was not permitted.</p><p><sup>153</sup>SmPHYP was provided by the &#x0201c;Instituto de Pesquisas Energ&#x000e9;ticas e Nucleares do Brasil&#x0201d; (IPEN). Both types of intervention were performed in the Nuclear Medicine Section following the bio-safety rules <xref ref-type="bibr" rid="b10-cln64_12p1187">10</xref> for the use of radioactive material. Procedures were always performed in the same fluoroscopy room. Threaded syringes were connected to a three-way tap and 50 &#x000d7; 8 mm needles were used to avoid reflux of the injected medication.</p></sec><sec><title>Procedure</title><p>Each patient underwent IAI guided by fluoroscopy while lying comfortably on their back. The knee was positioned at maximum extension with the needle entry point two centimeters from the upper-lateral angle of the patella subjected to eversion. Lidocaine (3 ml, 2%) with no vasoconstrictor was injected into the intra-articular region. Then, 3 to 5 ml of non-ionic iodated contrast medium was also injected. Distribution in the intra-articular recesses of the knee was viewed continuously by fluoroscopy. The Sm/TH group received 15 mCi injections of <sup>153</sup>SmPHYP diluted with 5 ml of 0.9% saline solution followed by 40 mg of TH. The TH group received 40 mg of TH alone.</p><p>A small amount of air was maintained in the syringe upon terminating infiltration so as to hinder subcutaneous reflux of the drugs. Systematic joint aspiration was performed prior to the injections in patients with synovial effusion. No patient had visual access to the procedure or preparation of the syringes.</p><p>All patients, regardless of group, remained at rest for four hours in a wheelchair in the Nuclear Medicine Section, and the knee was extended with the help of a splint.<xref ref-type="bibr" rid="b26-cln64_12p1187">26</xref> Patients were then transported to their homes and were told to remain at rest with a splint on the infiltrated knee for 48 h, only getting up from the bed to attend to their physiological needs.</p></sec><sec><title>Evaluation</title><p>Patients were evaluated by a blinded physician at baseline (T0) as well as 1, 4, 12, 32, and 48 weeks after intervention (T1, T4, T12, T32, and T48, respectively). The following instruments were applied during all assessment sessions: VAS for joint pain and swelling (range: 0&#x02013;10 cm), knee goniometry (flexion and extension), morning stiffness, knee circumference (cm), Likert scale of improvement (a lot of improvement, little improvement, unchanged, a little worse, much worse) according to the patient and the evaluator, percentage of improvement, Lequesne index,<xref ref-type="bibr" rid="b29-cln64_12p1187">29</xref> calls to the physician, hospital visits, and adverse effects and events.</p><p>The following assessment instruments were applied through T12: Brazilian version of the Functional subscale of the Stanford Health Assessment Questionnaire (HAQ),<xref ref-type="bibr" rid="b30-cln64_12p1187">30</xref> Brazilian version of the SF-36 generic quality of life questionnaire,<xref ref-type="bibr" rid="b31-cln64_12p1187">31</xref> Lequesne index,<xref ref-type="bibr" rid="b29-cln64_12p1187">29</xref> and use of non-steroidal anti-inflammatory drugs and oral corticosteroids.</p><p>The number of sodium diclofenac tablets and oral prednisone doses were counted at each time point, and average daily doses for these drugs were assessed. Patients were considered withdrawals if they interrupted the follow-up in the first month of the study; had altered DMARDs; or experienced an interruption of their disease for a period of two weeks or more. During the three-month follow-up period, the DMARDs were maintained stable, whereas prednisone and diclofenac doses could be altered according to need. After this period, there was flexibility for the following items: physiotherapy, acupuncture, infiltrations, and change in DMARDs according to the needs and activity of the disease.</p></sec><sec sec-type="methods"><title>Statistical Analysis</title><p>Data are presented as mean &#x000b1; standard deviation. Chi-square analysis was used to evaluate differences between categorical variables. The Mann-Whitney test was used for analysis of non-parametric numerical variables. ANOVA analysis was performed to compare numerical variables repeated over time. The significance level was set at p&#x0003c;0.05. The Tukey multiple comparison test was performed for intra-group analysis. ANOVA with non-parametric repeated measurements was used in the analysis of ordinal data of the Likert scale. Data were analyzed according to the intention-to-treat principle and patients with missing data had the previous evaluation data repeated.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>The sample was made up of 58 patients (60 knees). Two patients participated in the study twice and were randomized twice (once for each knee). The second randomization was for the contralateral knee and occurred three months after the intervention for the first knee. The data displayed in the tables refer to the number of knees and not the number of patients. There was no statistically significant difference between groups regarding joint, functional class, demographic, or disease-related variables at baseline (T0) (<xref ref-type="table" rid="t1-cln64_12p1187">Table 1</xref>).</p><p>The radiological assessment was done according to the Kellgren-Lawrence scale<xref ref-type="bibr" rid="b28-cln64_12p1187">28</xref> and no difference was found between the groups, even when the groups were stratified into five degrees (0 to 4) according to this scale (<xref ref-type="table" rid="t1-cln64_12p1187">Table 1</xref>).</p><p>Three patients were absent from the T32 reevaluation (2 from the Sm/TH group and 1 from the TH) and four were absent from the T48 reevaluation (1 from the Sm/TH Group and 3 from the TH group).</p><p>In the <bold>intra-group</bold> analysis in relation to T0 (initial time), there was a statistically significant improvement at all evaluation times for the VAS for pain and swelling; at T1 for morning stiffness; at T1, T4, and T12 for joint flexion; at T1 and T4 for joint extensions; and from T4 to T48 for knee circumference in both groups (<xref ref-type="table" rid="t2-cln64_12p1187">Table 2</xref>). In the <bold>inter-group</bold> analysis throughout the evolution of the study, no differences were observed between groups regarding the local variables (VAS for pain and swelling, morning stiffness, knee flexion, extension, and circumference) (<xref ref-type="table" rid="t2-cln64_12p1187">Table 2</xref>).</p><p>There were no statistical differences between the groups for the following variables: Likert scale of improvement according to patient and evaluator, percentage of improvement, HAQ (<xref ref-type="table" rid="t3-cln64_12p1187">Table 3</xref>) and SF-36 questionnaires, Lequesne index (<xref ref-type="table" rid="t3-cln64_12p1187">Table 3</xref>), use of non-steroidal anti-inflammatory drugs and oral corticosteroids (<xref ref-type="table" rid="t4-cln64_12p1187">Table 4</xref>), calls to the physician and hospital visits.</p><p>Side effects were divided into two groups: <bold><italic>adverse effects</italic></bold> were those cited by either the patient or evaluator as likely related to the procedure; <bold><italic>events</italic></bold> were situations of any nature cited by either the patient or evaluator. Twenty-two adverse effects were registered in the evolution of the patients, the most frequent of which was post-injection flare (6.7% of the initial sample) with an average duration of 2.25 d (1 to 4 d) after infiltration that did not persist through to the T1 evaluation. The Sm/TH group exhibited more adverse effects 1190 than the TH group at T1 (<italic>p&#x0003c;0.015</italic>), but in the evaluations T4 to T48 the number of adverse effects was similar in both groups. Three of the five adverse effects (60%) in the TH group occurred before the T1 evaluation.</p><p>A femur fracture occurred in one patient from the Sm/TH group with risk factors for osteoporosis. This fracture was considered a casual event and occurred after 11 mo of follow-up. There were no statistically significant differences between groups regarding events throughout the study (<xref ref-type="table" rid="t5-cln64_12p1187">Table 5</xref>).</p><p>One patient from the Sm/TH group required re-infiltration of the knee with TH after 8 mo, and 2 patients from the TH group required re-infiltration of the knee after three and eight months from the intervention due to the recurrence of arthritis (<italic>p</italic>= 1.00). After three months, 27 patients (14 from the Sm/TH group and 13 from the TH group; <italic>p=</italic> 0.795) modified the use of DMARDs due to activity of their disease.</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The effectiveness and cost benefit of RS for patients with chronic synovitis have not yet reached a consensus in the medical literature. Despite the fact that RS has a higher cost than IAI with GC, the benefit of its use is the impression of a greater response, longer duration of response in comparison to chemical synovectomy through corticosteroid use, and its use as an option for treatment of refractory synovitis.<xref ref-type="bibr" rid="b10-cln64_12p1187">10</xref>,<xref ref-type="bibr" rid="b12-cln64_12p1187">12</xref> In our study, <sup>153</sup>SmPHYP was chosen because it is available for use in our country and for its properties. <sup>153</sup>SmPHYP is a radionuclide with a half-life of 46.3 h and &#x003b2;<sup>-</sup> energy of 0.29 MeV, resulting in a maximum penetration of 3.1 mm and therapeutic penetration of 0.7 mm into soft tissue.<xref ref-type="bibr" rid="b25-cln64_12p1187">25</xref>,<xref ref-type="bibr" rid="b26-cln64_12p1187">26</xref> The <sup>153</sup>SmPHYP compound emits a small amount of gamma radiation, which is suitable for imaging by gamma camera equipment and is associated with low levels of leakage after injection, safe, and good tolerance.<xref ref-type="bibr" rid="b25-cln64_12p1187">25</xref>,<xref ref-type="bibr" rid="b26-cln64_12p1187">26</xref>,<xref ref-type="bibr" rid="b34-cln64_12p1187">34</xref> There is also a possible fibrotic action of this compound on the pannus, enabling more lasting control over inflammation. Therefore, use of this radioisotope is theoretically superior to the use of TH alone.</p><p>There are few controlled, randomized trials in the literature comparing RS with IAI of glucocorticosteroids. <sup>186</sup>Re is used for synovectomy of medium-sized joints and has been assessed in controlled, randomized prospective and retrospective trials that demonstrate its superiority to IAI of glucocorticosteroids.<xref ref-type="bibr" rid="b19-cln64_12p1187">19</xref>,<xref ref-type="bibr" rid="b20-cln64_12p1187">20</xref>,<xref ref-type="bibr" rid="b24-cln64_12p1187">24</xref> So far, there is no consensus about the superiority of RS with <sup>169</sup>Er (used in small joints) over IAI of glucocorticosteroids.<xref ref-type="bibr" rid="b21-cln64_12p1187">21</xref>,<xref ref-type="bibr" rid="b22-cln64_12p1187">22</xref> Synovectomy by <sup>90</sup>Y has been studied in some controlled trials and has been shown to be superior to IAI of saline solution,<xref ref-type="bibr" rid="b10-cln64_12p1187">10</xref>,<xref ref-type="bibr" rid="b13-cln64_12p1187">13</xref>&#x02013;<xref ref-type="bibr" rid="b15-cln64_12p1187">15</xref> but studies comparing it to IAI of glucocorticosteroids have had conflicting results.<xref ref-type="bibr" rid="b16-cln64_12p1187">16</xref>&#x02013;<xref ref-type="bibr" rid="b18-cln64_12p1187">18</xref> A systematic review regarding RS with <sup>90</sup>Y concluded that there is no clear evidence of greater efficacy of <sup>90</sup>Y over IAI of glucocorticosteroids despite its frequent use in cases of refractory synovitis.<xref ref-type="bibr" rid="b7-cln64_12p1187">7</xref> New radioisotopes such as Dysprosium-165 Ferric Hydroxide Macroaggregate (<sup>165</sup>Dy) and Holmium-166 (<sup>166</sup>Ho) have been developed, but their effectiveness and superiority have not yet been proven in clinical trials.<xref ref-type="bibr" rid="b32-cln64_12p1187">32</xref>,<xref ref-type="bibr" rid="b33-cln64_12p1187">33</xref></p><p>The only controlled, double-blinded study of <sup>153</sup>SmPHYP similar to the present study was carried out by O&#x02019; Duffy et al. (1999), who found no difference between the groups studied.<xref ref-type="bibr" rid="b26-cln64_12p1187">26</xref> However, sixty patients with different inflammatory arthropathies participated in this study and few assessment instruments were used.<xref ref-type="bibr" rid="b26-cln64_12p1187">26</xref> In the present study, only patients with RA participated and more objective instruments were used, rather than just scores, including those that assess inflammation, function, quality of life, subjective improvement, and adverse effects and events. The present study also found no statistically significant differences between groups for the diverse variables studied.</p><p>A trial with the same experimental design as the present study demonstrated through magnetic resonance a statistically greater reduction in synovitis of the knee in the group using IAI of TH alone in a three-month follow-up.<xref ref-type="bibr" rid="b34-cln64_12p1187">34</xref> However, it only analyzed evolution through an imaging method and for a much shorter follow-up period. Nonetheless, the findings of that study corroborate the impression that the addition of <sup>153</sup>SmPHYP to TH does not increase the effectiveness of the glucocorticosteroids when injected into the intra-articular region.<xref ref-type="bibr" rid="b34-cln64_12p1187">34</xref></p><p>Studies on <sup>153</sup>SmPHYP for RS describe no side effects attributed to the radioisotope.<xref ref-type="bibr" rid="b25-cln64_12p1187">25</xref>&#x02013;<xref ref-type="bibr" rid="b26-cln64_12p1187">26</xref> The present study found more adverse effects in the Sm/TH group than in the TH group, but the difference was only significant in the T1 evaluation <italic>(p</italic>&#x0003c;<italic>0.015)</italic> and the effects were mild with a short duration and spontaneous remission. Most of the side effects were systemic and were also described for IAI of glucocorticosteroids.<xref ref-type="bibr" rid="b6-cln64_12p1187">6</xref> Post-injection flare occurred at an equal frequency in both groups, with an average duration of 2.25 d (1 to 4 d), and these effects did not persist until T1 evaluation.</p><p>In the present comparison study of RS with <sup>153</sup>SmPHYP associated with TH and IAI of TH alone, no difference was found, which confirms the results of the study by O&#x02019; Duffy et al.<xref ref-type="bibr" rid="b26-cln64_12p1187">26</xref>.</p><p>The results show that RS with <sup>153</sup>SmPHYP associated with TH is not superior to IAI of HT alone, and that the positive effects may be attributed to the concomitant use of HT.<xref ref-type="bibr" rid="b13-cln64_12p1187">13</xref>&#x02013;<xref ref-type="bibr" rid="b16-cln64_12p1187">16</xref>,<xref ref-type="bibr" rid="b18-cln64_12p1187">18</xref></p><p>Some theories may explain the similar results between the groups studied: <sup>153</sup>SmPHYP penetration may not have been effective for the knee, which is a large joint, or its dosage may have been too small.</p><p>We conclude that IAI of <sup>153</sup>SmPHYP at a dosage of 15 mCi associated with TH was not superior to administration of TH alone for the treatment of synovitis of the knee in RA patients with a one-year follow-up. There is a need for studies with longer follow-up periods in order to more completely evaluate the benefit of <sup>153</sup>SmPHYP in these patients&#x02019; knees. <sup>153</sup>SmPHYP may be useful in medium-size joint, such as wrists, elbows, and ankles, because it exhibits tissue penetration similar to <sup>186</sup>Re, which is also used in these joints.<xref ref-type="bibr" rid="b35-cln64_12p1187">35</xref> Thus, further studies assessing higher doses in the knees and similar doses in medium-sized joints are important for determination of the true effectiveness of RS through <sup>153</sup>SmPHYP.</p></sec></body><back><ack><p>This work was supported by CNPq (Conselho Nacional de Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico, Brazil).</p></ack><ref-list><title>REFERENCES</title><ref id="b1-cln64_12p1187"><label>1.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wilder</surname><given-names>RL</given-names></name></person-group><article-title>Primer on rheumatic diseases</article-title><person-group person-group-type="editor"><name><surname>Shumacher</surname><given-names>HR</given-names></name><name><surname>Klippel</surname><given-names>JH</given-names></name><name><surname>Koopman</surname><given-names>WJ</given-names></name></person-group><source>Rheumatoid arthritis Epidemiology, pathology and pathogenesis</source><edition>10th ed</edition><publisher-loc>Atlanta</publisher-loc><publisher-name>Arthritis Foundation</publisher-name><year>1993</year><fpage>86</fpage><lpage>9</lpage></mixed-citation></ref><ref id="b2-cln64_12p1187"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eberhardt</surname><given-names>K</given-names></name><name><surname>Johnson</surname><given-names>PM</given-names></name><name><surname>Rydgren</surname><given-names>L</given-names></name></person-group><article-title>The occurrence and significance of hand deformities in early rheumatoid arthritis</article-title><source>Br J Rheumatol</source><year>1991</year><volume>30</volume><fpage>211</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">2049583</pub-id></mixed-citation></ref><ref id="b3-cln64_12p1187"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emery</surname><given-names>P</given-names></name></person-group><article-title>Treatment of rheumatoid arthritis</article-title><source>BMJ</source><year>2006</year><volume>332</volume><fpage>152</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">16424492</pub-id></mixed-citation></ref><ref id="b4-cln64_12p1187"><label>4.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hicks</surname><given-names>JE</given-names></name><name><surname>Gerber</surname><given-names>LH</given-names></name></person-group><article-title>Handbook of rheabilitative rheumatology</article-title><person-group person-group-type="editor"><name><surname>Hicks</surname><given-names>JE</given-names></name><name><surname>Nicholas</surname><given-names>JJ</given-names></name><name><surname>Swezey</surname><given-names>RL</given-names></name></person-group><source>Rheabilitative management of rheumatic diseases</source><publisher-loc>New York</publisher-loc><year>1998</year>; Copyright <fpage>81</fpage><lpage>110</lpage></mixed-citation></ref><ref id="b5-cln64_12p1187"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenning</surname><given-names>F</given-names></name><name><surname>Toffolo</surname><given-names>S</given-names></name><name><surname>de Assis</surname><given-names>MR</given-names></name><name><surname>Natour</surname><given-names>J</given-names></name></person-group><article-title>Brazil Patient knowledge Questionnaire (PKQ) and evaluatin of disease-specific knowledge in patient with rheumatoid arthritis</article-title><source>Clin Exp Rheumatol</source><year>2006</year><volume>24</volume><fpage>521</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17181920</pub-id></mixed-citation></ref><ref id="b6-cln64_12p1187"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gray</surname><given-names>RG</given-names></name><name><surname>Gottlieb</surname><given-names>NL</given-names></name></person-group><article-title>Intra-articular corticosteroids &#x02014; An updated assessment</article-title><source>Clin Orthop Rel Res</source><year>1983</year><volume>177</volume><fpage>235</fpage><lpage>63</lpage></mixed-citation></ref><ref id="b7-cln64_12p1187"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heuft-Dorenbosch</surname><given-names>LLJ</given-names></name><name><surname>Vet</surname><given-names>HCW</given-names></name><name><surname>Linder</surname><given-names>SV</given-names></name></person-group><article-title>Yttrium radiosynoviorthesis in the treatment of knee arthritis in rheumatoid arthritis: a systematic review</article-title><source>Ann Rheum Dis</source><year>2000</year><volume>59</volume><fpage>583</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10913051</pub-id></mixed-citation></ref><ref id="b8-cln64_12p1187"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blyth</surname><given-names>T</given-names></name><name><surname>Hunter</surname><given-names>JA</given-names></name><name><surname>Stirling</surname><given-names>A</given-names></name></person-group><article-title>Pain relief in the rheumatoid knee after steroid injection. A single-blind comparison of hydrocortisone succinate, and triamcinolone acetonide or hexacetonide</article-title><source>Br J Rheumatol</source><year>1994</year><volume>33</volume><fpage>461</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">8173851</pub-id></mixed-citation></ref><ref id="b9-cln64_12p1187"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fellinger</surname><given-names>K</given-names></name><name><surname>Schmid</surname><given-names>J</given-names></name></person-group><article-title>Die lokale Behandlung der rheumatischen Erkrankungen</article-title><source>Wien Z Inn Med</source><year>1952</year><volume>33</volume><fpage>351</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">13006334</pub-id></mixed-citation></ref><ref id="b10-cln64_12p1187"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>P</given-names></name><name><surname>Farahati</surname><given-names>J</given-names></name><name><surname>Reiners</surname><given-names>C</given-names></name></person-group><article-title>Radiosynovectomy in rheumatology, orthopedics and hemophilia</article-title><source>J Nucl Med</source><volume>46</volume><year>2005</year><issue>suppl 1</issue><fpage>48S</fpage><lpage>54S</lpage><pub-id pub-id-type="pmid">15653651</pub-id></mixed-citation></ref><ref id="b11-cln64_12p1187"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clunie</surname><given-names>G</given-names></name><name><surname>Ell</surname><given-names>PJ</given-names></name></person-group><article-title>A survey of radiation synovectomy in Europe, 1991&#x02013;1993</article-title><source>Eur J Nucl Med.</source><year>1995</year><volume>22</volume><fpage>970</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7588951</pub-id></mixed-citation></ref><ref id="b12-cln64_12p1187"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clunie</surname><given-names>G</given-names></name><name><surname>Fischer</surname><given-names>M</given-names></name></person-group><article-title>EANM Procedure guidelines for radiosynovectomy</article-title><source>Eur J Nucl Med</source><year>2003</year><volume>30</volume><fpage>BP12</fpage><lpage>16</lpage></mixed-citation></ref><ref id="b13-cln64_12p1187"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bridgman</surname><given-names>JF</given-names></name><name><surname>Bruckner</surname><given-names>F</given-names></name><name><surname>Bleehen</surname><given-names>NM</given-names></name></person-group><article-title>Radioactive yttrium in the treatment of rheumatoid knee effusions</article-title><source>Ann Rheum Dis</source><year>1971</year><volume>30</volume><fpage>180</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">5569439</pub-id></mixed-citation></ref><ref id="b14-cln64_12p1187"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bridgman</surname><given-names>JF</given-names></name><name><surname>Bruckner</surname><given-names>F</given-names></name><name><surname>Eisen</surname><given-names>V</given-names></name><name><surname>Tucker</surname><given-names>A</given-names></name><name><surname>Bleehen</surname><given-names>NM</given-names></name></person-group><article-title>Irradiation of the synovium in the treatment of rheumatoid arthritis</article-title><source>Q J Med, New Series</source><year>1973</year><volume>XLII</volume> 166:<fpage>357</fpage><lpage>67</lpage></mixed-citation></ref><ref id="b15-cln64_12p1187"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delbarre</surname><given-names>MF</given-names></name><name><surname>Alice Le G&#x000f4;</surname><given-names>M</given-names></name><name><surname>Menkes</surname><given-names>MMC</given-names></name><name><surname>Aignan</surname><given-names>M</given-names></name></person-group><article-title>Preuve, par etude statistique &#x0201c;en double aveugle&#x0201d;, de l&#x02019;effet th&#x000e9;rapeutique d&#x02019;un colloide charg&#x000e9; d&#x02019;yttrium radioactive (<sup>90</sup>Y) dans l&#x02019;arthrite rhumatoide du genou</article-title><source>C R Hebd Seances Acad Sci D</source><year>1974</year><volume>279</volume><fpage>1051</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">4219308</pub-id></mixed-citation></ref><ref id="b16-cln64_12p1187"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szanto</surname><given-names>E</given-names></name></person-group><article-title>Long-term follow-up of yttrium-treated knee-joint arthritis</article-title><source>Scan J Rheumatol</source><year>1977</year><volume>6</volume><fpage>209</fpage><lpage>12</lpage></mixed-citation></ref><ref id="b17-cln64_12p1187"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>EN</given-names></name><name><surname>Bellamy</surname><given-names>N</given-names></name><name><surname>Fryday-Field</surname><given-names>K</given-names></name><name><surname>Disney</surname><given-names>T</given-names></name><name><surname>Driedger</surname><given-names>A</given-names></name><name><surname>Hobby</surname><given-names>K</given-names></name></person-group><article-title>Double-blind randomized controlled trial and six-year open follow-up of yttrium-90 radiosynovectomy versus triamcinolone hexacetonide in persistent rheumatoid knee synovitis</article-title><source>Inflammopharmacology</source><year>1992</year><volume>1</volume><fpage>231</fpage><lpage>8</lpage></mixed-citation></ref><ref id="b18-cln64_12p1187"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jahangier</surname><given-names>ZN</given-names></name><name><surname>Jacobs</surname><given-names>JWG</given-names></name><name><surname>Lafeber</surname><given-names>FPJG</given-names></name><name><surname>Moolenburgh</surname><given-names>JD</given-names></name><name><surname>Swen</surname><given-names>WAA</given-names></name><name><surname>Bruyn</surname><given-names>GAW</given-names></name><etal/></person-group><article-title>Is radiation synovectomy for arthritis of the knee more efective than intraarticular treatment with glucocorticoids?</article-title><source>Arthritis Rheum</source><year>2005</year><volume>52</volume><fpage>3391</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">16255016</pub-id></mixed-citation></ref><ref id="b19-cln64_12p1187"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f6;bel</surname><given-names>D</given-names></name><name><surname>Gratz</surname><given-names>S</given-names></name><name><surname>Von Rothkirch</surname></name><name><surname>Becker</surname><given-names>W</given-names></name><name><surname>Willert</surname><given-names>H-G</given-names></name></person-group><article-title>Radiosynoviorthesis with rhenium-186 in rheumatoid arthritis: a prospective study of three treatment regimens</article-title><source>Rheumatol int</source><year>1997</year><volume>17</volume><fpage>105</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9352604</pub-id></mixed-citation></ref><ref id="b20-cln64_12p1187"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tebib</surname><given-names>JG</given-names></name><name><surname>Manil</surname><given-names>LM</given-names></name><name><surname>M&#x000f6;dder</surname><given-names>G</given-names></name><name><surname>Verrier</surname><given-names>P</given-names></name><name><surname>De Rycke</surname><given-names>Y</given-names></name><name><surname>Bonmartin</surname><given-names>A</given-names></name><etal/></person-group><article-title>Better results with rhenium- 186 radiosynoviorthesis than with cortivazol in rheumatoid arthritis (RA): a two-year follow up randomized controlled multicentre study</article-title><source>Clin Exp Rheumatol</source><year>2004</year><volume>22</volume><fpage>609</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">15485015</pub-id></mixed-citation></ref><ref id="b21-cln64_12p1187"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menkes</surname><given-names>CJ</given-names></name><name><surname>Le Go</surname><given-names>A</given-names></name><name><surname>Verrier</surname><given-names>P</given-names></name><name><surname>Aignan</surname><given-names>M</given-names></name><name><surname>Delbarre</surname><given-names>F</given-names></name></person-group><article-title>Double-blind study of erbium169 injection (synoviorthesis) in rheumatoid digital joints</article-title><source>Ann Rheum Dis</source><year>1997</year><volume>36</volume><fpage>254</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">327948</pub-id></mixed-citation></ref><ref id="b22-cln64_12p1187"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gumpel</surname><given-names>JM</given-names></name><name><surname>Matthews</surname><given-names>SA</given-names></name><name><surname>Fisher</surname><given-names>M</given-names></name></person-group><article-title>Synoviorthesis with erbium-169: a double- blind controlled comparison of erbium-169 with corticosteroid</article-title><source>Ann Rheum Dis</source><year>1979</year><volume>38</volume><fpage>341</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">386961</pub-id></mixed-citation></ref><ref id="b23-cln64_12p1187"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahan</surname><given-names>A</given-names></name><name><surname>M&#x000f6;dder</surname><given-names>G</given-names></name><name><surname>Menkes</surname><given-names>CJ</given-names></name><name><surname>Verrier</surname><given-names>P</given-names></name><name><surname>Devaux</surname><given-names>J-Y</given-names></name><name><surname>Bonmartin</surname><given-names>A</given-names></name><etal/></person-group><article-title><sup>186</sup>Erbium-citrate synoviorthesis after failure of local corticosteroid injection to treat rheumatoid arthritis &#x02013; affected finger joints</article-title><source>Clin Exp Rheumatol</source><year>2004</year><volume>22</volume><fpage>722</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">15638046</pub-id></mixed-citation></ref><ref id="b24-cln64_12p1187"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Zant</surname><given-names>FM</given-names></name><name><surname>Jahangier</surname><given-names>ZN</given-names></name><name><surname>Moolenburgh</surname><given-names>JD</given-names></name><name><surname>Swen</surname><given-names>WAA</given-names></name><name><surname>Boer</surname><given-names>RO</given-names></name><name><surname>Jacobs</surname><given-names>JWG</given-names></name></person-group><article-title>Clinical effect of radiation synovectomy of the upper extremity joint: a randomized, double-blind, placebo-controlled study</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2007</year><volume>34</volume><fpage>212</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16951956</pub-id></mixed-citation></ref><ref id="b25-cln64_12p1187"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clunie</surname><given-names>G</given-names></name><name><surname>Lui</surname><given-names>D</given-names></name><name><surname>Cullum</surname><given-names>I</given-names></name><name><surname>Edwards Jo</surname><given-names>CW</given-names></name><name><surname>Ell</surname><given-names>PJ</given-names></name></person-group><article-title>Clinical outcome after one year following samarium-153 particulate hydroxyapatite radiation synovectomy</article-title><source>Scan J Rheumatol</source><year>1996</year><volume>25</volume><fpage>360</fpage><lpage>6</lpage></mixed-citation></ref><ref id="b26-cln64_12p1187"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Duffy</surname><given-names>EK</given-names></name><name><surname>Clunie</surname><given-names>GPR</given-names></name><name><surname>Lui</surname><given-names>D</given-names></name><name><surname>Edwards</surname><given-names>JCW</given-names></name><name><surname>Ell</surname><given-names>PJ</given-names></name></person-group><article-title>Double Blind Glucocorticoid controlled trial of samarium-153 particulate hydroxyapatite radiation synovectomy for chronic Knee synovitis</article-title><source>Ann Rheum Dis</source><year>1999</year><volume>58</volume><fpage>554</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">10460188</pub-id></mixed-citation></ref><ref id="b27-cln64_12p1187"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnett</surname><given-names>FC</given-names></name><name><surname>Edworth</surname><given-names>SM</given-names></name><name><surname>Blok</surname><given-names>DA</given-names></name><name><surname>McShane</surname><given-names>DJ</given-names></name><name><surname>Fries</surname><given-names>JF</given-names></name><name><surname>Cooper</surname><given-names>NS</given-names></name><etal/></person-group><article-title>The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis</article-title><source>Arthritis Rheum</source><year>1988</year><volume>31</volume><fpage>315</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">3358796</pub-id></mixed-citation></ref><ref id="b28-cln64_12p1187"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kellgren</surname><given-names>JH</given-names></name><name><surname>Lawrence</surname><given-names>JS</given-names></name></person-group><article-title>Radiological assessment of osteoarthrosis</article-title><source>Ann Rheum Dis</source><year>1957</year><volume>16</volume><fpage>494</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">13498604</pub-id></mixed-citation></ref><ref id="b29-cln64_12p1187"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lequesne</surname><given-names>MG</given-names></name><name><surname>Mery</surname><given-names>C</given-names></name><name><surname>Samson</surname><given-names>M</given-names></name><name><surname>Gerard</surname><given-names>P</given-names></name></person-group><article-title>Indexes of severity for osteoarthritis of the hip and knee. Validation--value in comparison with other assessment tests</article-title><source>Scand J Rheumatol</source><year>1987</year><volume>65</volume><issue>Suppl</issue><fpage>85</fpage><lpage>9</lpage></mixed-citation></ref><ref id="b30-cln64_12p1187"><label>30.</label><mixed-citation publication-type="journal"><article-title>Crosscultural reliability of the physical ability dimension of the health assessment questionnaire</article-title><source>J Rheumatol</source><year>1990</year><volume>17</volume><fpage>813</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">2388204</pub-id></mixed-citation></ref><ref id="b31-cln64_12p1187"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciconelli</surname><given-names>RM</given-names></name><name><surname>Ferraz</surname><given-names>MB</given-names></name><name><surname>Santos</surname><given-names>W</given-names></name><name><surname>Mein&#x000e3;o</surname><given-names>I</given-names></name><name><surname>Quaresma</surname><given-names>MR</given-names></name></person-group><article-title>Tradu&#x000e7;&#x000e3;o para a l&#x000ed;ngua portuguesa e valida&#x000e7;&#x000e3;o do question&#x000e1;rio gen&#x000e9;rico de avalia&#x000e7;&#x000e3;o de qualidade de vida SF-36 (Brasil F-36)</article-title><source>Rev Bras Reumatol</source><year>1999</year><volume>39</volume><fpage>143</fpage><lpage>9</lpage></mixed-citation></ref><ref id="b32-cln64_12p1187"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edmonds</surname><given-names>J</given-names></name><name><surname>Smart</surname><given-names>R</given-names></name><name><surname>Laurent</surname><given-names>R</given-names></name><name><surname>Butler</surname><given-names>P</given-names></name><name><surname>Brooks</surname><given-names>P</given-names></name><name><surname>Hoschl</surname><given-names>R</given-names></name><etal/></person-group><article-title>A comparative study of the safety and efficacy of Dysprosium-165 hydroxide macro-aggregate and Yttrium-90 silicate colloid in radiation synovectomy- a multicentre double blind clinical trial</article-title><source>Br J Rheumatol</source><year>1994</year><volume>33</volume><fpage>947</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">7921756</pub-id></mixed-citation></ref><ref id="b33-cln64_12p1187"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Suh</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>JD</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>SK</given-names></name></person-group><article-title>MR evaluation of radiation synovectomy of the knee by means of intra-articular injection of Holmium-166-Chitosan Complex in patients with rheumatoid arthritis: results at 4-month follow-up</article-title><source>Korean J Radiol</source><year>2003</year><volume>4</volume><fpage>170</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">14530646</pub-id></mixed-citation></ref><ref id="b34-cln64_12p1187"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clunie</surname><given-names>GPR</given-names></name><name><surname>Wilkinson</surname><given-names>ID</given-names></name><name><surname>Lui</surname><given-names>D</given-names></name><name><surname>Hall-Craggs</surname><given-names>MA</given-names></name><name><surname>Paley</surname><given-names>MN</given-names></name><name><surname>Edwards</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Changes in articular synovial lining volume measured by magnetic resonance in a randomized, double-blind, controlled trial of intra-articular samarium-153 particulate hydroxyapatite for chronic knee synovitis</article-title><source>Rheumatology (Oxford)</source><year>1999</year><volume>38</volume><fpage>113</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10342622</pub-id></mixed-citation></ref><ref id="b35-cln64_12p1187"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boerbooms</surname><given-names>AM</given-names></name></person-group><article-title>Clinical outcome after one year following samarium-153 particulate hydroxyapatite radiation synovectomy</article-title><source>Scand J Rheumatol</source><year>1997</year><volume>26</volume><fpage>136</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9137332</pub-id></mixed-citation></ref></ref-list></back><floats-group><table-wrap id="t1-cln64_12p1187" position="float"><label>Table 1</label><caption><p>Characteristics of the sample at baseline</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"/><th valign="top" align="left" rowspan="1" colspan="1">Sm/TH Group (n=30)</th><th valign="top" align="left" rowspan="1" colspan="1">TH Group (n=30)</th><th valign="top" align="left" rowspan="1" colspan="1">p<sup><xref ref-type="table-fn" rid="tfn2-cln64_12p1187">#</xref></sup></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age, years (Mean&#x000b1;SD)</td><td valign="top" align="left" rowspan="1" colspan="1">54.8 (&#x000b1;8.04)</td><td valign="top" align="left" rowspan="1" colspan="1">54.4 (&#x000b1;7.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0.491</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Gender (Women/ Men)</td><td valign="top" align="left" rowspan="1" colspan="1">25:5</td><td valign="top" align="left" rowspan="1" colspan="1">27:3</td><td valign="top" align="left" rowspan="1" colspan="1">0.447</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Race (White)</td><td valign="top" align="left" rowspan="1" colspan="1">24</td><td valign="top" align="left" rowspan="1" colspan="1">20</td><td valign="top" align="left" rowspan="1" colspan="1">0.11</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Disease duration, years (Mean&#x000b1;SD)</td><td valign="top" align="left" rowspan="1" colspan="1">12.07 (<bold>&#x000b1;</bold>9.4)</td><td valign="top" align="left" rowspan="1" colspan="1">13.2 (<bold>&#x000b1;</bold>12)</td><td valign="top" align="left" rowspan="1" colspan="1">0.677</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Rheumatoid Factor (positive) (%)</td><td valign="top" align="left" rowspan="1" colspan="1">19 (63.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">20 (66.7%)</td><td valign="top" align="left" rowspan="1" colspan="1">0.787</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Functional class II: III</td><td valign="top" align="left" rowspan="1" colspan="1">9:21</td><td valign="top" align="left" rowspan="1" colspan="1">13:17</td><td valign="top" align="left" rowspan="1" colspan="1">0.284</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DMARDS (%)</td><td valign="top" align="left" rowspan="1" colspan="1">28 (93.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">27 (90%)</td><td valign="top" align="left" rowspan="1" colspan="1">0.640</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Methotrexate (%)</td><td valign="top" align="left" rowspan="1" colspan="1">24 (80%)</td><td valign="top" align="left" rowspan="1" colspan="1">23 (76.6%)</td><td valign="top" align="left" rowspan="1" colspan="1">0.754</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Chloroquine diphosphate (%)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (13.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (13.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sulfasalazine (%)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (6.7%)</td><td valign="top" align="left" rowspan="1" colspan="1">0.554</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Leflunomide (%)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (20%)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (26.7)</td><td valign="top" align="left" rowspan="1" colspan="1">0.542</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Infliximab (%)</td><td valign="top" align="left" rowspan="1" colspan="1">0 (0%)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (3.3%)</td><td valign="top" align="left" rowspan="1" colspan="1">0.313</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Time from past infiltration of the knee (months) Mean&#x000b1;SD</td><td valign="top" align="left" rowspan="1" colspan="1">12.4 (<bold>&#x000b1;</bold>15.4)</td><td valign="top" align="left" rowspan="1" colspan="1">15.4 (<bold>&#x000b1;</bold>16.9)</td><td valign="top" align="left" rowspan="1" colspan="1">0.954</td></tr><tr><td valign="top" align="left" colspan="4" rowspan="1">Kellgren-Lawrence Classification</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Grade 0</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">3</td><td valign="top" align="left" rowspan="1" colspan="1">0.269</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Grade 1</td><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Grade 2</td><td valign="top" align="left" rowspan="1" colspan="1">6</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Grade 3</td><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Grade 4</td><td valign="top" align="left" rowspan="1" colspan="1">4</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn1-cln64_12p1187"><p>TH group: triamcinolone hexacetonide (TH); Sm/TH group: <sup>153</sup>SmPHYP + TH; SD=standard deviation;</p></fn><fn id="tfn2-cln64_12p1187"><label><sup>#</sup></label><p><italic>p</italic> = Pearson&#x02019;s chi-square, Mann-Whitney test</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-cln64_12p1187" position="float"><label>Table 2</label><caption><p>Assessment of clinical parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Time Points (weeks)</th><th valign="top" align="left" rowspan="1" colspan="1">Sm/TH Group (n=30) Mean&#x000b1;SD</th><th valign="top" align="left" rowspan="1" colspan="1">TH Group (n=30) Mean&#x000b1;SD</th><th valign="top" align="center" rowspan="1" colspan="1">Inter-group p<xref ref-type="table-fn" rid="tfn4-cln64_12p1187">**</xref></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" colspan="2" rowspan="1">VAS for pain (0&#x02013;10 cm)</td><td valign="top" align="center" rowspan="1" colspan="1">0.607</td></tr><tr><td valign="top" align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T0</bold></td><td valign="top" align="left" rowspan="1" colspan="1">6.8 (1.4)</td><td valign="top" align="left" rowspan="1" colspan="1">6.8 (1.4)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T1</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>2.3 (2.4)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>2.0 (2.1)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></bold></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T4</bold></td><td valign="top" align="left" rowspan="1" colspan="1">2.9 (2.6)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">2.6 (2.6)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T12</bold></td><td valign="top" align="left" rowspan="1" colspan="1">3.4 (2.8)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">3.0 (2.5)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T32</bold></td><td valign="top" align="left" rowspan="1" colspan="1">4.5 (3.0)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">4.3 (3.2)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T48</bold></td><td valign="top" align="left" rowspan="1" colspan="1">3.8 (3.2)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">3.8 (3.3)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" colspan="2" rowspan="1"><bold>VAS for swelling (0&#x02013;10 cm)</bold></td><td valign="top" align="center" rowspan="1" colspan="1">0.179</td></tr><tr><td valign="top" align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T0</bold></td><td valign="top" align="left" rowspan="1" colspan="1">3.9 (2.0)</td><td valign="top" align="left" rowspan="1" colspan="1">3.8 (1.8)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T1</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>1.6 (1.7)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>1.0 (1.4)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></bold></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T4</bold></td><td valign="top" align="left" rowspan="1" colspan="1">1.1 (1.1)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.9 (1.4)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T12</bold></td><td valign="top" align="left" rowspan="1" colspan="1">1.3 (1.3)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">0.7 (1.0)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T32</bold></td><td valign="top" align="left" rowspan="1" colspan="1">1.6 (1.5)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.2 (1.4)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T48</bold></td><td valign="top" align="left" rowspan="1" colspan="1">1.5 (1.7)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.0 (1.6)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" colspan="2" rowspan="1"><bold>Morning stiffness</bold></td><td valign="top" align="center" rowspan="1" colspan="1">0.413</td></tr><tr><td valign="top" align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T0</bold></td><td valign="top" align="left" rowspan="1" colspan="1">14.2 (14.9)</td><td valign="top" align="left" rowspan="1" colspan="1">32.5 (55.2)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T1</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>4.8 (12.9)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>1.9 (5.8)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></bold></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T4</bold></td><td valign="top" align="left" rowspan="1" colspan="1">6.2 (13.9)</td><td valign="top" align="left" rowspan="1" colspan="1">4.1 (11.5)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T12</bold></td><td valign="top" align="left" rowspan="1" colspan="1">6.6 (22.0)</td><td valign="top" align="left" rowspan="1" colspan="1">2.2 (5.0)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T32</bold></td><td valign="top" align="left" rowspan="1" colspan="1">12.2 (26.2)</td><td valign="top" align="left" rowspan="1" colspan="1">26.9 (76.6)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T48</bold></td><td valign="top" align="left" rowspan="1" colspan="1">8.8 (15.5)</td><td valign="top" align="left" rowspan="1" colspan="1">11.5 (33.3)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" colspan="2" rowspan="1"><bold>Knee flexion (grade)</bold></td><td valign="top" align="center" rowspan="1" colspan="1">0.661</td></tr><tr><td valign="top" align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T0</bold></td><td valign="top" align="left" rowspan="1" colspan="1">116.1 (14.6)</td><td valign="top" align="left" rowspan="1" colspan="1">115.03 (14.5)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T1</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>119.4 (16.7)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>121.97 (16.3)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></bold></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T4</bold></td><td valign="top" align="left" rowspan="1" colspan="1">120.5 (15.3)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">123.17 (16.4)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T12</bold></td><td valign="top" align="left" rowspan="1" colspan="1">120.4 (12.5)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">121.93 (16.9)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T32</bold></td><td valign="top" align="left" rowspan="1" colspan="1">117.6 (15.1)</td><td valign="top" align="left" rowspan="1" colspan="1">120.3 (16.9)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T48</bold></td><td valign="top" align="left" rowspan="1" colspan="1">118.0 (15.2)</td><td valign="top" align="left" rowspan="1" colspan="1">119.7 (18.0)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" colspan="2" rowspan="1"><bold>Knee extension (grade)</bold></td><td valign="top" align="center" rowspan="1" colspan="1">0.096</td></tr><tr><td valign="top" align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T0</bold></td><td valign="top" align="left" rowspan="1" colspan="1">7.7 (8.5)</td><td valign="top" align="left" rowspan="1" colspan="1">3.1 (5.3)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T1</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>4.0 (5.9)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>1.8 (4.0)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></bold></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T4</bold></td><td valign="top" align="left" rowspan="1" colspan="1">3.5 (5.2)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.9 (4.0)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T12</bold></td><td valign="top" align="left" rowspan="1" colspan="1">4.4 (5.8)</td><td valign="top" align="left" rowspan="1" colspan="1">3.0 (7.3)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T32</bold></td><td valign="top" align="left" rowspan="1" colspan="1">6.5 (8.3)</td><td valign="top" align="left" rowspan="1" colspan="1">3.3 (6.0)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T48</bold></td><td valign="top" align="left" rowspan="1" colspan="1">6.6 (8.7)</td><td valign="top" align="left" rowspan="1" colspan="1">3.6 (6.8)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" colspan="2" rowspan="1"><bold>Knee circumference (cm)</bold></td><td valign="top" align="center" rowspan="1" colspan="1">0.875</td></tr><tr><td valign="top" align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T0</bold></td><td valign="top" align="left" rowspan="1" colspan="1">40.0 (3.8)</td><td valign="top" align="left" rowspan="1" colspan="1">39.9 (3.3)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T1</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>38.4 (7.3)</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>39.3 (3.9)</bold></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T4</bold></td><td valign="top" align="left" rowspan="1" colspan="1">39.3 (4.0)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">38.9 (3.8)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T12</bold></td><td valign="top" align="left" rowspan="1" colspan="1">39.7 (3.8)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">39.1 (4.3)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T32</bold></td><td valign="top" align="left" rowspan="1" colspan="1">39.6 (4.0)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">39.2 (4.2)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T48</bold></td><td valign="top" align="left" rowspan="1" colspan="1">39.3 (4.1)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">38.9 (4.5)<xref ref-type="table-fn" rid="tfn5-cln64_12p1187">*</xref></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn3-cln64_12p1187"><p><bold>TH group</bold>: triamcinolone hexacetonide (TH); <bold>Sm/TH group</bold>: <sup>153</sup>SmPHYP + TH; <bold>VAS:</bold> visual analog scale; <bold>SD</bold>=standard deviation;</p></fn><fn id="tfn4-cln64_12p1187"><label>**</label><p>ANOVA for repeated measurements;</p></fn><fn id="tfn5-cln64_12p1187"><label>*</label><p><italic>p&#x0003c; 0.05</italic> (intra-group p in relation to T0): Tukey multiple comparison test</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-cln64_12p1187" position="float"><label>Table 3</label><caption><p>Knee function according to the Lequesne and HAQ questionnaires</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Time Points (weeks)</bold></th><th valign="top" align="left" rowspan="1" colspan="1">Sm/TH Group (n=30) Mean&#x000b1;SD</th><th valign="top" align="left" rowspan="1" colspan="1">TH Group (n=30) Mean&#x000b1;SD</th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Inter-group p<italic><xref ref-type="table-fn" rid="tfn7-cln64_12p1187">**</xref></italic></bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><bold>Lequesne index</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.889</td></tr><tr><td valign="top" align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T0</bold></td><td valign="top" align="left" rowspan="1" colspan="1">16.6 (3.2)</td><td valign="top" align="left" rowspan="1" colspan="1">17.2 (2.8)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T1</bold></td><td valign="top" align="left" rowspan="1" colspan="1">11.8 (4.5)<xref ref-type="table-fn" rid="tfn8-cln64_12p1187">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">11.0 (5.0)<xref ref-type="table-fn" rid="tfn8-cln64_12p1187">*</xref></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T4</bold></td><td valign="top" align="left" rowspan="1" colspan="1">11.6 (4.8)<xref ref-type="table-fn" rid="tfn8-cln64_12p1187">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">11.2 (5.0)<xref ref-type="table-fn" rid="tfn8-cln64_12p1187">*</xref></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T12</bold></td><td valign="top" align="left" rowspan="1" colspan="1">12.0 (4.4)<xref ref-type="table-fn" rid="tfn8-cln64_12p1187">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">11.6 (5.1)<xref ref-type="table-fn" rid="tfn8-cln64_12p1187">*</xref></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T32</bold></td><td valign="top" align="left" rowspan="1" colspan="1">13.2 (4.8)<xref ref-type="table-fn" rid="tfn8-cln64_12p1187">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">13.4 (4.7)<xref ref-type="table-fn" rid="tfn8-cln64_12p1187">*</xref></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T48</bold></td><td valign="top" align="left" rowspan="1" colspan="1">13.2 (4.4)<xref ref-type="table-fn" rid="tfn8-cln64_12p1187">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">13.1 (4.5)<xref ref-type="table-fn" rid="tfn8-cln64_12p1187">*</xref></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><bold>HAQ</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.077</td></tr><tr><td valign="top" align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T0</bold></td><td valign="top" align="left" rowspan="1" colspan="1">1.3 (0.5)</td><td valign="top" align="left" rowspan="1" colspan="1">1.6 (0.5)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T1</bold></td><td valign="top" align="left" rowspan="1" colspan="1">1.0 (0.5)<xref ref-type="table-fn" rid="tfn8-cln64_12p1187">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.2 (0.5)<xref ref-type="table-fn" rid="tfn8-cln64_12p1187">*</xref></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T4</bold></td><td valign="top" align="left" rowspan="1" colspan="1">1.0 (0.5)<xref ref-type="table-fn" rid="tfn8-cln64_12p1187">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.2 (0.6)<xref ref-type="table-fn" rid="tfn8-cln64_12p1187">*</xref></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T12</bold></td><td valign="top" align="left" rowspan="1" colspan="1">1.2 (0.5)<xref ref-type="table-fn" rid="tfn8-cln64_12p1187">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.4 (0.7)<xref ref-type="table-fn" rid="tfn8-cln64_12p1187">*</xref></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn6-cln64_12p1187"><p><bold>TH group</bold>: triamcinolone hexacetonide (TH); <bold>Sm/TH group</bold>: <sup>153</sup>SmPHYP + TH; <bold>SD</bold>=standard deviation;</p></fn><fn id="tfn7-cln64_12p1187"><label>**</label><p>ANOVA for repeated measurements;</p></fn><fn id="tfn8-cln64_12p1187"><label>*</label><p><italic>p&#x0003c; 0.05</italic> (p intra-group p in relation to T0): Tukey multiple comparison test</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-cln64_12p1187" position="float"><label>Table 4</label><caption><p>Use of number of sodium diclofenac tablets and oral prednisone (doses)</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Time Points (weeks)</bold></th><th valign="top" align="left" rowspan="1" colspan="1">Sm/TH Group (n=30) Mean&#x000b1;SD</th><th valign="top" align="left" rowspan="1" colspan="1">TH Group (n=30) Mean&#x000b1;SD</th><th valign="top" align="center" rowspan="1" colspan="1"><bold>Inter-group p<italic><xref ref-type="table-fn" rid="tfn10-cln64_12p1187">**</xref></italic></bold></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" colspan="2" rowspan="1"><bold>NSAIDS, tablets/day</bold> (Mean&#x000b1;SD)</td><td valign="top" align="center" rowspan="1" colspan="1">0.782</td></tr><tr><td valign="top" align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T0</bold></td><td valign="top" align="left" rowspan="1" colspan="1">0.63 (1.07)</td><td valign="top" align="left" rowspan="1" colspan="1">0.63 (0.99)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T1</bold></td><td valign="top" align="left" rowspan="1" colspan="1">0.63 (0.99)</td><td valign="top" align="left" rowspan="1" colspan="1">0.64 (0.87)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T4</bold></td><td valign="top" align="left" rowspan="1" colspan="1">0.80 (1.01)</td><td valign="top" align="left" rowspan="1" colspan="1">0.77 (0.97)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T12</bold></td><td valign="top" align="left" rowspan="1" colspan="1">0.80 (1.04)<xref ref-type="table-fn" rid="tfn11-cln64_12p1187">*</xref></td><td valign="top" align="left" rowspan="1" colspan="1">1.07 (1.15)<xref ref-type="table-fn" rid="tfn11-cln64_12p1187">*</xref></td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" colspan="2" rowspan="1"><bold>Prednisone, mg/day</bold> (Mean&#x000b1;SD)</td><td valign="top" align="center" rowspan="1" colspan="1">0.064</td></tr><tr><td valign="top" align="left" colspan="4" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T0</bold></td><td valign="top" align="left" rowspan="1" colspan="1">5.1 (6.0)</td><td valign="top" align="left" rowspan="1" colspan="1">7.1 (5.3)</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T1</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>5.3 (5.8)</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>6.6 (5.7)</bold></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T4</bold></td><td valign="top" align="left" rowspan="1" colspan="1">5.9 (5.5)</td><td valign="top" align="left" rowspan="1" colspan="1">7.5 (5.0)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>T12</bold></td><td valign="top" align="left" rowspan="1" colspan="1">5.5 (5.4)</td><td valign="top" align="left" rowspan="1" colspan="1">7.6 (5.3)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn9-cln64_12p1187"><p><bold>TH group</bold>: triamcinolone hexacetonide (TH); <bold>Sm/TH group</bold>: <sup>153</sup>SmPHYP + TH; <bold>NSAID</bold>= non-steroidal anti-inflammatory drug; <bold>SD</bold>=standard deviation;</p></fn><fn id="tfn10-cln64_12p1187"><label>**</label><p>ANOVA for repeated measurements;</p></fn><fn id="tfn11-cln64_12p1187"><label>*</label><p><italic>p&#x0003c; 0.05</italic> (p intra-group p in relation to T0): Tukey multiple comparison test</p></fn></table-wrap-foot></table-wrap><table-wrap id="t5-cln64_12p1187" position="float"><label>Table 5</label><caption><p>Distribution of the types of adverse effects and events between groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>ADVERSE EFFECTS</bold></th><th valign="top" align="center" rowspan="1" colspan="1">Sm/TH Group (n=30)</th><th valign="top" align="center" rowspan="1" colspan="1">TH Group (n=30)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Post-injection flare</bold> (T1)</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Urticaria</bold> (T1)</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Pruritus</bold> (T1, T4)</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Chills</bold> (T1)</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Headache</bold> (T1)</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Rash on face</bold> (T1)</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Sweating</bold> (T1)</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Hot flashes</bold> (T1)</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Hypertensive peak</bold> (T1, T4)</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Insomnia</bold> (T4)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Swelling of lower limbs</bold> (T12)</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Increased instability</bold> (T12,T48)</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" colspan="3" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>EVENTS</bold></td><td valign="top" align="center" rowspan="1" colspan="1">Sm/TH Group (n=30)</td><td valign="top" align="center" rowspan="1" colspan="1">TH Group (n=30)</td></tr><tr><td valign="top" align="left" colspan="3" rowspan="1"><hr/></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Polaciury</bold> (T1)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Urinary tract infection</bold> (T1)</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Acute sinus condition</bold> (T4)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Asthma episode</bold> (T4)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Vaginal Candidiasis</bold> (T32)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Femur fracture</bold> (T48)</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Detached retina</bold> (T48)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><fn id="tfn12-cln64_12p1187"><p><bold>TH group</bold>: triamcinolone hexacetonide (TH); <bold>Sm/TH group</bold>: <sup>153</sup>SmPHYP + TH; <bold>SD</bold>= standard deviation</p></fn></table-wrap-foot></table-wrap></floats-group></article>